NASDAQ:MYL - Mylan Stock Price, Forecast & News

Mylan trades on the NASDAQ under the ticker symbol "MYL."

Mylan NV (NASDAQ:MYL) announced its earnings results on Tuesday, November, 5th. The company reported $1.17 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.03. The company earned $2.96 billion during the quarter, compared to the consensus estimate of $3.01 billion. Mylan had a return on equity of 18.80% and a net margin of 0.42%. The company's revenue was up 3.5% on a year-over-year basis. During the same period last year, the firm earned $1.25 earnings per share. View Mylan's Earnings History.

Mylan is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Mylan.

Mylan updated its FY19 earnings guidance on Tuesday, November, 5th. The company provided earnings per share guidance of $4.20-4.40 for the period, compared to the Thomson Reuters consensus estimate of $4.27. The company issued revenue guidance of $11.5-12.0 billion, compared to the consensus revenue estimate of $11.61 billion.

18 equities research analysts have issued 12-month price targets for Mylan's shares. Their forecasts range from $18.00 to $36.00. On average, they anticipate Mylan's share price to reach $27.26 in the next year. This suggests a possible upside of 23.1% from the stock's current price. View Analyst Price Targets for Mylan.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 7 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mylan.

News coverage about MYL stock has been trending somewhat negative this week, InfoTrie reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mylan earned a media sentiment score of -1.6 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Mylan.

Mylan saw a decline in short interest in December. As of December 31st, there was short interest totalling 19,680,000 shares, a decline of 17.3% from the December 15th total of 23,800,000 shares. Based on an average daily trading volume, of 6,520,000 shares, the days-to-cover ratio is presently 3.0 days. Currently, 3.8% of the company's shares are sold short. View Mylan's Current Options Chain.

Some companies that are related to Mylan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mylan investors own include Gilead Sciences (GILD), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Allergan (AGN), Micron Technology (MU), Starbucks (SBUX), Netflix (NFLX), NVIDIA (NVDA), Intel (INTC) and General Electric (GE).

Mylan's stock is owned by many different of retail and institutional investors. Top institutional investors include Commerzbank Aktiengesellschaft FI (0.07%), State of Alaska Department of Revenue (0.03%), Alpine Global Management LLC (0.02%), Convergence Investment Partners LLC (0.01%), Nisa Investment Advisors LLC (0.01%) and Cumberland Advisors Inc. (0.01%). Company insiders that own Mylan stock include Anthony Mauro, Goulds Bruce, Melina E Higgins, Paul Campbell, Rajiv Malik, Richard A Mark, Robert J Coury and Sjoerd S Vollebregt. View Institutional Ownership Trends for Mylan.

MYL stock was sold by a variety of institutional investors in the last quarter, including Commerzbank Aktiengesellschaft FI, Nisa Investment Advisors LLC, State of Alaska Department of Revenue, Janney Montgomery Scott LLC and Zeke Capital Advisors LLC. View Insider Buying and Selling for Mylan.

MYL stock was purchased by a variety of institutional investors in the last quarter, including Alpine Global Management LLC, Convergence Investment Partners LLC, Campbell & CO Investment Adviser LLC, Altfest L J & Co. Inc., Cumberland Advisors Inc. and Huntington National Bank. Company insiders that have bought Mylan stock in the last two years include Melina E Higgins, Richard A Mark, Robert J Coury and Sjoerd S Vollebregt. View Insider Buying and Selling for Mylan.

Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MYL stock can currently be purchased for approximately $22.14.

Mylan has a market capitalization of $11.43 billion and generates $11.43 billion in revenue each year. The company earns $352.50 million in net income (profit) each year or $4.58 on an earnings per share basis. Mylan employs 35,000 workers across the globe.View Additional Information About Mylan.

The official website for Mylan is http://www.mylan.com/.

Mylan's mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The company can be reached via phone at 724-514-1800 or via email at [email protected]